全文获取类型
收费全文 | 12707篇 |
免费 | 794篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 73篇 |
儿科学 | 312篇 |
妇产科学 | 307篇 |
基础医学 | 1861篇 |
口腔科学 | 203篇 |
临床医学 | 1331篇 |
内科学 | 2258篇 |
皮肤病学 | 157篇 |
神经病学 | 1267篇 |
特种医学 | 401篇 |
外国民族医学 | 1篇 |
外科学 | 1458篇 |
综合类 | 438篇 |
一般理论 | 5篇 |
预防医学 | 1612篇 |
眼科学 | 172篇 |
药学 | 824篇 |
中国医学 | 12篇 |
肿瘤学 | 846篇 |
出版年
2023年 | 72篇 |
2022年 | 110篇 |
2021年 | 280篇 |
2020年 | 173篇 |
2019年 | 254篇 |
2018年 | 303篇 |
2017年 | 221篇 |
2016年 | 233篇 |
2015年 | 282篇 |
2014年 | 442篇 |
2013年 | 550篇 |
2012年 | 800篇 |
2011年 | 932篇 |
2010年 | 454篇 |
2009年 | 393篇 |
2008年 | 812篇 |
2007年 | 791篇 |
2006年 | 697篇 |
2005年 | 728篇 |
2004年 | 710篇 |
2003年 | 577篇 |
2002年 | 597篇 |
2001年 | 304篇 |
2000年 | 290篇 |
1999年 | 257篇 |
1998年 | 135篇 |
1997年 | 113篇 |
1996年 | 96篇 |
1995年 | 98篇 |
1994年 | 60篇 |
1993年 | 39篇 |
1992年 | 124篇 |
1991年 | 106篇 |
1990年 | 132篇 |
1989年 | 115篇 |
1988年 | 93篇 |
1987年 | 83篇 |
1986年 | 85篇 |
1985年 | 97篇 |
1984年 | 72篇 |
1983年 | 68篇 |
1981年 | 38篇 |
1979年 | 75篇 |
1978年 | 38篇 |
1977年 | 38篇 |
1974年 | 47篇 |
1973年 | 39篇 |
1972年 | 42篇 |
1971年 | 37篇 |
1969年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh 《Journal of cystic fibrosis》2019,18(2):271-277
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献6.
7.
We have previously reported the time trends, design and interventions in randomised controlled trials (RCTs) in cystic fibrosis (CF) from 1961 through 1997 [Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D, Randomised controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr Pulmonol 2000, 29:1-7.]. We maintain an ongoing register of all RCTs and controlled clinical trials (CCTs) in CF and have noted that in the five years since 1997 there has been a 48% increase in published trials. We aimed to assess whether this increase has been associated with an improvement in design quality. All RCTs and CCTs from 1961-2002 were assessed. Two epochs were then compared, 1961-1997 and 1998-2002. For each trial we recorded the design, participant numbers and the intervention studied. 261 trials in 1998-2002 were compared with 544 trials in 1961-1997. Comparing the two epochs a similar proportion of trials were parallel, double-blind and placebo controlled; also the median number of participants was similar. In the later epoch 25% of trials were multicentre, compared with 11% previously. Whilst this recent increase in clinical trials in CF is welcome, this has not been associated with improvements in quality. The trend for an increasing proportion of trials to be multicentre is encouraging. There are however, still deficiencies in the design of clinical trials in CF. 相似文献
8.
Tracy Brightman Jiang-Hong Ye Elizabeth Ortiz-Jimenez Edward J. Flynn Wen-Hsien Wu Joseph J. McArdle 《Brain research》1995,678(1-2)
While adult mice receiving picrotoxin (PTX) alone responded with clonic and tonic-clonic seizures, this response was greatly suppressed for mice simultaneously injected with 2,3-butanedione monoxime (BDM). For example, 60% and 10% of the mice convulsed when injected (i.p.) with 3.0 mg/kg PTX alone or PTX plus 205 mg/kg of BDM, respectively. In contrast, a non-oxime analogue of BDM, 2,3-butanedione (BTD), did not have this anticonvulsant effect. In order to explore the basis for the anticonvulsant effect of BDM, we recorded GABA-activated currents (IGABA) of frontal cortical as well as ventromedial hypothalamic neurons before, during and after exposure to this oxime. BDM had a biphasic effect on concentrations (100 μM-40 mM) decreased and lower concentrations (0.01 μM–0.001 μM) potentiatedIGABA; these effects of BDM reversed upon washout of the oxime. In contrast, BTD had no effect onIGABA. Finally, when 0.001 μM BDM, 10–30 μM PTX and GABA were co-applied the inhibitory effect of the toxin onIGABA was markedly suppressed. These data suggest that the anticonvulsant effect of oximes involves facilitation of the inhibitory action of GABA. 相似文献
9.
10.
Tracy D Gunter Donald W Black Janet Zwick Stephan Arndt 《Annals of clinical psychiatry》2004,16(4):195-200
BACKGROUND: Methamphetamine abuse has become a major public health problem as demonstrated by increases in the number of emergency room visits, substance abuse treatment episodes, and arrests attributable to methamphetamine manufacture and abuse. We examine the effectiveness of conventional substance abuse treatment in the recovery of individuals seeking voluntary treatment for methamphetamine abuse. METHODS: At the request of the Iowa Department of Public Health, the Iowa Consortium for Substance Abuse Research and Evaluation contacted clients who had been admitted to voluntary treatment for methamphetamine abuse. Staff from the Consortium asked subjects to volunteer for follow-up interviews at designated intervals following admission. Agency staff conducted interviews based on the Mini International Neuropsychiatric Interview (MINI) at admission and at designated intervals and reported results to the Consortium for analysis. RESULTS: Subjects were predominantly Caucasian and over one half were female with an average age of 30 years. The criminal justice system was a primary referral source. Reported psychiatric symptoms dropped substantially in the first 60 days following admission and appeared to remain low at 6 and 12 months. Most clients reported abstinence and employment and denied arrests at the 6-month interview. Outcomes were not correlated with psychiatric symptoms. CONCLUSIONS: Psychiatric symptoms improved over time with usual substance abuse treatment. There was no evidence that referral by the court system or symptoms of antisocial personality disorder affected outcome. Conventional treatment resulted in sobriety, employment, and fewer arrests at 6 and 12 months following treatment. 相似文献